Decoy Therapeutics is trading at $1.98, up 11.86%, in pre-market; no clear catalyst for the October 5 rise appeared in available search results. - The latest reported company update was preclinical data for its DCOY-CoV program, published before this session; it does not establish a reason for the move. - An October 2 report of a sharp consensus price-target cut is prior context, not a clear explanation for Monday’s gain. - Major index futures were nearly flat, so broad-market direction does not clearly account for the move.